OUR COMPANY

ABOUT US

THIS IS SHAPE

We are passionate about building highly innovative healthcare solutions. Our team members have an entrepreneurial spirit paired with longstanding experience in international life-science companies as entrepreneurs, scientists and innovators. We are united by a culture of strong partnerships and execution.

MANAGEMENT

Arin Ghasparian, PhD

President & CEO

Arin is a passionate life-sciences entrepreneur, innovator, and a proven business leader with longstanding experience in the biopharmaceutical industry. He founded several pharmaceutical and biotech companies developing innovative next-generation vaccines, nano-medicines, and immunotherapeutic drugs. Prior to founding Shape he was CEO at Virometix, a Swiss biotech company that he started with two academic co-founders to develop next-generation fully synthetic vaccines for RSV and other pathogens, and led the transition from a research-focused startup to a clinical-stage company. Arin is an established expert in synthetic vaccine development and bio-nanotechnology. He invented several patents, technologies, and vaccine and drug candidates. Arin holds a PhD in Chemistry from the University of Zurich, Switzerland.

Armando Zuniga, PhD

CSO

Armando has more than 20 years scientific experience in the academia and vaccine industry. In his last position as CSO of Virometix, he oversaw the research and development of synthetic peptide-based vaccine candidates for RSV, HPV and pneumococcal diseases. Prior to Virometix he headed the preclinical development activities at Redbiotec and led small and large R&D teams at Berna Biotech and Crucell (Johnson & Johnson). He co-developed the measles-virus (MV) vector technology and various recombinant and synthetic virus-like particle-based vaccine candidates for SARS CoV-1, HIV-1, HPV, RSV and immuno-oncology applications. Armando also authored numerous scientific publications and is co-inventor of several patents. Armando holds a PhD in Microbiology.

Daniel Geffken, MBA

CFO

Daniel is a proven leader of life science companies with more than 30 years of experience steering strategy, finance and operations across all stages of the corporate life cycle. As Co-founder and Managing Director of Danforth Advisors, he leads a team of more than 90 consultants in strategic CFO advisory, accounting and operational support for over 150 clients, ranging from life science start-ups to publicly traded companies with $1 billion+ market capitalizations. He has served as CFO and executive-level advisor to numerous companies, including Apellis Pharmaceuticals, Cabaletta Bio, Editas Medicine, Homology Medicines, Promedior and Transkaryotic Therapies. Over the course of his career, Daniel has raised nearly $2 billion in equity and debt securities for life science companies. He holds a BS from The Wharton School, University of Pennsylvania, and an MBA from Harvard Business School.

JOIN US AT THE FOREFRONT OF IMMUNOTHERAPY DEVELOPMENT

We always seek exceptional talents, out-of-the box thinkers, go-getters and self-starters. Do you want to contribute to the success of this venture and are interested to learn more about working with us?

Please contact us here →

Registered Office in the U.S.:

Registered Office in Switzerland:

Privacy Statement

Impressum